Logotype for NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma Company (NAMS) investor relations material

NewAmsterdam Pharma Company Stifel Virtual Cardiometabolic Forum summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for NewAmsterdam Pharma Company N.V.
Stifel Virtual Cardiometabolic Forum summary30 Sep, 2025

Clinical trial progress and outcomes

  • All pivotal lipid-lowering registration studies (BROADWAY, BROOKLYN, TANDEM) are completed and published in leading journals.

  • PREVAIL, the major outcomes trial, is fully enrolled with baseline characteristics mirroring BROADWAY and event rates tracking as expected.

  • PREVAIL requires a minimum 2.5-year participation per patient, resulting in a longer median follow-up than recent trials.

  • PREVAIL is four times larger and longer than BROADWAY, aiming to confirm the 21% MACE reduction seen previously.

  • Additional studies, including REMBRANDT (CT angio trial with Harvard) and an Alzheimer’s biomarker sub-study, are ongoing.

Regulatory and commercial strategy

  • European filings for both monotherapy and fixed-dose combination have been accepted, with potential approvals expected in the second half of next year.

  • U.S. launch is planned to coincide with PREVAIL outcomes data; final readout timing will be clearer next year as event rates are monitored.

  • Discussions with the FDA regarding data readout and approval process are scheduled for next year.

Scientific insights and data interpretation

  • BROADWAY showed a 21% reduction in MACE, supported by Kaplan-Meier curves and mediation analysis linking LDL, LDL particles, and Lp(a) to outcomes.

  • LDL particles, especially small ones, are considered better predictors of cardiovascular risk than LDL-C alone, with CETP inhibition dramatically reducing these particles.

  • Ongoing analyses in large databases and clinical trials aim to further validate the predictive value of LDL particles and ApoB.

Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.

Next NewAmsterdam Pharma Company earnings date

Logotype for NewAmsterdam Pharma Company N.V.
Q3 20256 Nov, 2025
Your earnings 
season toolkit.
Download
Free on both iOS & Android.

Next NewAmsterdam Pharma Company earnings date

Logotype for NewAmsterdam Pharma Company N.V.
Q3 20256 Nov, 2025

The essential earnings season companion

The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

Live calls and transcripts

Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.

Find what you need faster

Search for any keyword across all transcripts simultaneously.

Easily store key findings

Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Your watchlist. Your dashboard.

Follow the companies that matter to you. Get a personalized feed with real-time updates.

Be the first to know

Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.

Consensus estimates

Access analyst consensus estimates, valuation multiples, and revenue segments splits.

All IR material in one place

The easiest way to stay updated during earnings season.

Global coverage

All events from public companies. Live and recorded.

Just click and listen

No webcast links. No manual registrations.

Research anytime, anywhere

Built for professionals. Loved by everyone. Try our free mobile app.

excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com

Frequently asked questions

NewAmsterdam Pharma Company N.V. is a clinical-stage biopharmaceutical company based in the Netherlands, focusing on the development of oral and non-statin medicines for patients at high risk of cardiovascular disease. Its leading product candidate is obicetrapib, a next-generation, oral, and low-dose cholesteryl ester transfer protein (CETP) inhibitor, currently in various stages of clinical trials. The company's mission is aimed at improving patient care in populations with metabolic diseases where currently approved therapies have not been sufficiently successful or well tolerated, with a significant focus on creating a potent, cost-effective, and convenient LDL-lowering therapy. The company is headquartered in Naarden, the Netherlands, and its shares are listed on the Nasdaq.

Quartr provides global coverage of all investor relation material from public companies.

  • Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

  • Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.

  • Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.

Yes, the Quartr mobile app is free on both iOS and Android.

Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.

Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.

Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.

Explore our global coverage